The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.

MAbs · 2023 · PMC9897756 · PMID 36727218

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

For example, in cases where the target expression is high, the advantage provided by a molecule with a higher 4–1BB-to-target binding site ratio may not be significant.

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.